Study of a new drug combo for advanced lung cancer after immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding a cholesterol-lowering drug to a combination of two other drugs can help people with advanced non-small cell lung cancer whose cancer has grown after prior immunotherapy. It aims to find a new treatment option for those who have run out of standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 80 years old.
- You must have advanced non-small cell lung cancer that has grown after previous treatment with an immunotherapy drug like Keytruda or Opdivo.
- Your cancer must not have certain gene mutations (EGFR, ALK, ROS1, RET).
- You cannot have had prior treatment with an anti-angiogenesis drug like Avastin.
- You must be in good overall health, able to care for yourself, and have adequate organ function.
- You cannot have active autoimmune disease or certain other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (sintilimab and anlotinib) for people with extensive-stage small cell lung cancer that has gotten worse after prior immunotherapy. The goal is to see if this combination can help control the cancer.
This trial is testing a new combination of treatments, including an immune drug (sintilimab) and a cholesterol-lowering drug (tafolecimab), along with chemotherapy, for people with advanced lung cancer that no longer responds to standard immunotherapy.
This trial tests a new combination therapy for people with advanced squamous non-small cell lung cancer. It adds sintilimab (an immunotherapy) and rh-endostatin (a drug that blocks blood supply to tumors) to standard chemotherapy, hoping to improve outcomes.
This study tests whether giving sintilimab (an immune therapy) combined with bevacizumab (a blood-vessel–targeting medicine) plus chemotherapy before surgery can improve outcomes for resectable lung cancer. It’s meant for people with specific lung cancer types and good health for surgery, and it avoids certain cancer types and immune-related risks.
This study tests a combination of two drugs (QL1706 and bevacizumab) with or without chemotherapy for people with advanced non-squamous lung cancer whose cancer worsened after prior immunotherapy. It may offer a new option for those with low PD-L1 levels.
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy to shrink inoperable stage IIIC lung cancer. The goal is to make the cancer small enough to remove with surgery and improve survival.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.